Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genmab has reported additional encouraging duration of response data from one of its HuMax-CD4 phase II studies treating patients with mycosis fungoides, a type of skin cancer.
Subscribe to our email newsletter
Data from all patients in the study showed a median response duration of more than 45 weeks. Furthermore, analysis of the time to response showed that 85% of the responding patients obtained clinical response within eight weeks.
Additionally, previously released data was analyzed to assess the relation between dose and the serum concentration of HuMax-CD4 (zanolimumab) measured immediately before the next treatment (trough values). Increasing doses of HuMax-CD4 resulted in increased trough values. Furthermore, a 55% response rate was achieved in patients reaching lesser than or equal to 10mu g/ml serum concentration compared to only 6% in patients not reaching this serum level.
“This latest set of duration of response data is very encouraging and indicates that HuMax-CD4 may be effective in treating cutaneous T-cell lymphoma (CTCL) patients with mycosis fungoides, especially at higher doses,” said Dr Lisa Drakeman, CEO of Genmab.